SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies informs about press release

04 Oct 2024 Evaluate
Indoco Remedies has informed that it enclosed a Press release regarding receipt of final approval from USFDA, for the Company’s Abbreviated New Drug Application for Cetirizine Hydrochloride Tablets USP, 10 mg (OTC), to market a generic equivalent of Zyrtec Allergy Tablets, 10 mg of Johnson & Johnson Consumer Inc.

The above information is a part of company’s filings submitted to BSE.

Indoco Remedies Share Price

209.90 0.70 (0.33%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×